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Prevention of osteoporotic refractures in regional Australia 
Abstract 
Objective: Clinical guidelines recommend that patients who sustain a minimal trauma fracture 
(MTF) should receive a bone mineral density (BMD) scan and bisphosphonate (or equivalent) 
therapy if diagnosed with osteoporosis.  A pilot fracture liaison service (FLS) was implemented 
in regional NSW to improve adherence to the guidelines.  
Design: prospective cohort study with an historical control 
Setting: primary care 
Participants: Control (n=47) and cohort (n=93) groups comprised patients consenting to 
interview who presented with a MTF to the major referral hospital four months before and twelve 
months after FLS implementation, respectively.   
Main outcome measures: Primary outcome measures were the rates of BMD scans and anti-
osteoporotic medication initiation/review after MTF.  Hospital admission data were also 
examined to determine death and refracture rates for all patients presenting during the study 
period with a primary diagnosis of MTF within three years of their initial fracture. 
Results: Although there was no improvement in BMD scanning rates, the reported rate of 
medication initiation/review after fracture was significantly higher (p<0.05) in the FLS cohort.  
However, once adjusted for age, this association was not significant (p=0.086). There was a 
lower refracture rate during the cohort period (p=0.013), however there were significantly more 
deaths (p=0.035) within three years of initial fracture.  When deaths were taken into account via 
competing risk regression, patients in the cohort period were significantly less likely to refracture 
than those in the control period (Hazard ratio = 0.576, p=0.032). 
Conclusions: A rurally-based nurse-led FLS was associated with modest improvement after 
MTF.  Consideration should be given to ways to strengthen the model of care to improve 
outcomes.     
Keywords: Bisphosphonates, Bone mineral density, Fracture liaison service, Minimal trauma 
fracture, Refracture 
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What is already known on this subject?  
● Despite a significant proportion of the Australian population being affected by osteoporosis, a 
large gap exists between the recommended guidelines and current practice for MTF, and this is 
often greater in rural and remote areas.  
● Specialised osteoporosis fracture liaison services (FLS) can be effective in identifying and 
guiding patients to appropriate services for osteoporosis management 
● Rural communities may have limited access to specialist outpatient services, which are a 
feature of successful metropolitan-based FLS 
 
What does this study add? 
 
A nurse-led FLS without an associated specialist outpatient clinic:  
● can be implemented in a rural location, 
● was associated with a modest improvement in medication initiation/review after MTF 
and significantly lower refracture rates, 
● requires strengthening to achieve optimal treatment after MTF. 
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Introduction 
 
It has been estimated that more than 2.2 million Australians are affected by an osteoporosis-
related condition1.  However, due to the silent nature of the disease, in 2011-2012 only 3.3% of 
the Australian population were diagnosed with osteoporosis2.  One of the consequences of 
osteoporosis is the occurrence of minimal trauma fractures (MTF), a fracture resulting from a fall 
from a standing height or less.  In 2009, there were almost 87,000 hospital admissions for MTF 
in Australia3. Mortality rates significantly increase after sustaining a MTF. In the first five years 
after a MTF, increases in absolute mortality above expected have been estimated at 1.3-13.2 
and 2.7-22.3 per 100 person years in females and males respectively4. Sustaining a MTF also 
carries significant morbidity with a reduction in quality of life and loss of independence5. 
 
Effective strategies for reducing the risk of refracture in MTF patients focus on identifying 
patients at risk, diagnosing osteoporosis, and implementing treatment5. Australian clinical 
guidelines currently recommend that MTF patients should receive assessment of their bone 
mineral density (BMD) with dual-energy x-ray absorptiometry (DXA) scanning6. The guidelines 
also recommend bisphosphonate or equivalent therapy for all MTF patients diagnosed with 
osteoporosis or osteopenia6 as these agents are effective in reducing refractures in high-risk 
patients7. Supplemental medications such as vitamin D and calcium alone have a minimal effect 
on reducing fracture risk in patients with osteoporosis8.  
 
Despite the significant proportion of the Australian population affected by osteoporosis, a large 
gap exists between the recommended guidelines and current practice for MTF patients3-13. 
Furthermore, BMD scanning rates after MTF have been found to be lower in rural and remote 
populations14. Specialised osteoporosis fracture liaison services (FLS) can be effective at 
identifying and guiding patients to appropriate services for osteoporosis management15-18. 
However, the majority of this research is conducted in metropolitan centres and does not 
address rural challenges. 
 
A recent study has described a rural intervention for osteoporotic fracture prevention. The Coffs 
Fracture Prevention Clinic was established in NSW in response to a proposed model of care 
developed by the NSW Agency for Clinical Innovation (ACI)19. This intervention involved a 
fracture liaison coordinator (FLC) in combination with a specialist clinic for osteoporosis 
management after MTF.  
 
Around the same time, an FLS was also developed in the Murrumbidgee Local Health District 
(MLHD) located in the rural south west of NSW20 in response to the ACI model of care. The 
service employed a part-time FLC who identified patients during their hospital admission to the 
Wagga Wagga Rural Referral Hospital (WWRRH) and contacted them to provide information on 
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osteoporosis and falls prevention strategies. The FLC also communicated with the patient’s 
general practitioner to indicate that the patient would benefit from osteoporosis-specific 
investigations and management if appropriate.  In this region, a specialist clinic was not 
available and was not included in the intervention.    
 
This study was undertaken to evaluate the effectiveness of this nurse-led FLS. It was 
hypothesised that the implementation of the FLS would lead to an increased rate of BMD 
scanning after MTF and higher rates of appropriate pharmacotherapy for osteoporosis when 
diagnosed. 
 
Method 
 
All patients aged over 45 years who were admitted with a MTF to the WWRRH during the first 
12 months after the implementation of the FLS in September 2011 (FLS cohort group) or during 
the four months preceding the FLS (control period) were eligible for participation.  Minimal 
trauma (fall from a standing height or less) was verified from the description of the injury in the 
electronic records. Specific fractures included in the search were: femur (condyle, shaft, neck, 
subtrochanteric, intertrochanteric and subcapital fractures), tibia and fibula, ankle, pelvis, 
humerus and wrist.  Patients were excluded if they had a pathological fracture (vertebral, 
clavicle and rib) or if they were deceased. Prior to the implementation of the FLS, patients would 
be discharged from hospital for follow up in orthopaedic specialist rooms, registrar outpatient 
clinics or by general practitioners and no specific advice was routinely provided in relation to 
further investigation for osteoporosis. 
 
Study participants were recruited initially by mail. A second round of letters was sent to increase 
participation, followed by a round of questionnaires asking the same questions. A telephone 
interview or postal survey was carried out for willing participants. All patients were contacted 
within a year of their initial MTF and their post-fracture osteoporosis management was 
assessed. In the interview (or questionnaire), patients were asked whether they had received a 
BMD scan, and whether appropriate anti-osteoporosis pharmacotherapy (bisphosphonate or 
equivalent therapy) had been reviewed or initiated. These outcomes were compared between 
recruited patients in the control and cohort groups.   
 
De-identified interview and survey data were collected and analysed using SPSS Version 20 
(SPSS Inc, Chicago, USA) and OpenEpi: Open Source Epidemiologic Statistics for Public 
Health, Version 2.3.1 (Atlanta, USA) (www.OpenEpi.com). Two tailed p-values were used and a 
value of <0.05 was considered significant. Confidence intervals were set at 95%. Patient 
demographics were analysed using frequency distribution, Pearson Chi-square tests (or 
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Fishers’ exact test) and independent samples t-tests.  Binary logistic regression was used to 
adjust for differences in age between the control and cohort survey groups. 
 
In addition, to further assess the possible effectiveness of the FLS, it was decided to determine 
the rates of refracture and death (within three years of initial fracture) for all patients with MTF 
before and after the implementation of the FLS using hospital admissions data.  All patients who 
sustain fractures within the catchment area who need to be admitted are received by this 
regional referral hospital.  Patients suffering major trauma, or with secondary diagnoses of 
fracture and patients who suffered multiple fractures were excluded from the analyses.  In line 
with the rest of this study, pathological fractures were excluded.  Differences in refracture and 
death between control and cohort periods were determined using Pearson’s Chi-Square test.  
Competing risks regression (via STATA v14, StataCorp LP, College Station, Texas 
USA www.stata.com) was used to determine if there was a difference in refracture rate (within 
three years of initial fracture) between groups while taking deaths into account.   
 
Ethics approval was granted by The University of Notre Dame Australia Human Research 
Ethics Committee (HREC) and the Greater Western HREC. The research was conducted in 
accordance with the ethical standards of the Declaration of Helsinki.  
 
Results 
 
Patients (n=483) were identified from medical records as having met the inclusion criteria.  Of 
these, 10 were identified as having suffered a major trauma, 12 fractures were secondary 
diagnoses and a further 42 died before recruitment.  Therefore, there were 419 eligible survey 
participants; these were contacted irrespective of whether or not they had been contacted by 
the FLS.  Data were obtained from 140 patients, a 33.4% response rate.  The fracture type 
characteristics of patients who were eligible for inclusion were similar to those of recruited 
participants, with a predominance of female patients (~75%).  However, patients recruited to 
this study were significantly younger than the non-recruited patients (p=0.003), with an average 
of 72.8 years (SD 11.8).  Non-recruited participants were older, with an average of 76.7 years 
(SD 12.9). 
 
The characteristics of eligible and recruited patients are presented in Table 1. Although there 
was no difference in mean age between eligible patients in the control group and eligible 
patients in the cohort group, the recruited control group was significantly older than the recruited 
cohort group (p=0.034, t(138)=2.142). Femoral fractures were the most common fracture type 
identified.  There were no significant differences in gender or fracture types between the groups.  
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There were no differences between recruited patients in the control and cohort groups in terms 
of the level of BMD scanning conducted nor the type of medication taken for their bones (Table 
2).  Overall, 41% of patients had received a BMD scan after their MTF and 78% had ever had a 
BMD scan.  Just over 30% of recruited patients reported being on no medications for 
osteoporosis, while 33% reported being on supplements (Ca2+ and/or vitamin D) and the 
remaining 37% on bisphosphonates or equivalent.  Patients in the FLS cohort group were more 
likely to have had their medications initiated or reviewed following fracture [X2(1)=3.900, 
p=0.048] than patients in the control group.  However, once age was adjusted for, this 
association was no longer significant (p=0.086). Almost 43% of patients in the cohort group had 
their medications reviewed versus 25% of patients in the control group.   
 
From the hospital admissions data, it was found that within three years of their initial fracture, 
59/456 (12.9%) patients had refractured the same or a different bone, with significantly fewer 
refractures overall during the FLS cohort period [X2(1)=6.162, p=0.013] (Table 3).  Fewer of 
those patients presenting with femur fracture during the cohort period refractured within three 
years (p=0.002) than patients presenting during the control period.  There were no differences 
for the other fracture types. 
 
However, there were more deaths during the cohort period [X2(1)=4.427, p=0.035) (Table 4).  
Overall, 18% of patients died within three years of their initial fracture.  There were no 
differences in deaths when comparing individual fractures.  Mean age (obtained from hospital 
admissions data) in the two groups were similar [77.1 (SD 13.1) in the control period and 75.9 
(SD 12.5) in the cohort period].  When deaths were taken into account via competing risk 
regression, patients in the cohort period were significantly less likely to refracture than patients 
in the control period (Hazard ratio = 0.576, 95%CI 0.348-0.953, p=0.032) (Figure 1).  The 
probability of refracture within three years was around 11% in the cohort group versus almost 
20% in the control group.  
 
Discussion 
 
Recently, Fraser and Wong (2016)19 reported the effectiveness of a regional osteoporosis 
model of care involving an FLC and a specialist clinic.  One quarter (25.4%) of eligible patients 
attended and 88% of these patients commenced bone protective therapy.  In our nurse-led 
model of care, without the support of a specialist clinic, only a modest improvement was 
observed. This study complements the Coffs Harbour study19 as it evaluated a different model 
in the rural setting wherein 33.4% of eligible patients were surveyed and it was found that 
medication initiation or review was increased from 25.5% in the control period to 42.6% in the 
cohort period. 
 
7 
 
The association towards improved management in FLS cohort patients in this study is 
consistent with a meta-analysis by Ganda et al.21 which reviewed the evidence relating to 
different models of care available for osteoporosis in order to assess their effectiveness at 
increasing BMD scans and bisphosphonate treatment rates in post MTF patients.  
 
The rate of BMD testing in our control group (40%) was much higher than reported in similar 
studies. One study based in a northern NSW regional hospital reported that 22% of patients 
received a BMD scan after their MTF11. The rates of BMD scanning for control groups in the 
Ganda et al. meta-analysis were between 9.2% and 23.8%20. The average bisphosphonate 
initiation rates for control groups in previously reported studies are around 7.5%21. The baseline 
management rates of the control group within this study were higher than what were expected 
based on studies with similar patient demographics and models of care11,12,21. This 
demonstrates the importance of using a control group to evaluate the outcome of service 
interventions. Without the presence of the control group, the success of the model may have 
been overestimated as it would have been judged against similar studies with lower rates in 
their control or intervention groups.  
 
There was a modest improvement in the level of medication initiation or review following MTF in 
the FLS cohort, however, there was no difference in the type of medication being taken for their 
bones.  Although Australian guidelines recommend the use of bisphosphonate or equivalent 
therapy for all MTF patients diagnosed with osteoporosis6, the use of supplements alone for the 
treatment of osteoporosis in patients after a MTF was found to be high in both the control and 
cohort groups. Nearly a third of the patients were receiving calcium or vitamin D supplements as 
the only form of medication even though supplementation therapy alone has been shown to 
have minimal effect in preventing refractures22-24. 
 
The pilot FLS program was implemented in this region due to the high public health promotion 
and support for osteoporosis management by a group of local health care providers20.  
However, this service did not involve medical specialist outpatient clinics.  Ganda et al.21 reports 
that such limited interventions results in modest improvements in clinical outcomes if any and 
that more funding and a more intensive intervention would result in greater improvements in 
clinical outcomes.  However, as this study only examined the pilot FLS during the first 12 
months of implementation, the skill and confidence of the FLC and the acceptance of the 
intervention among primary care providers may take some time to reach full effect. In addition, it 
appears that the FLS was only able to contact less than half of the patients who had fractures 
during the FLS cohort period.   
 
In addition to data from the telephone survey, refracture and death rates were also determined 
using  hospital admissions data for all patients who sustained a MTF during the control and 
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cohort periods.  This was done to address some of the issues of recall bias, non-randomisation 
of groups and inherent differences in patients who opt to participate. Patients in the cohort 
period had a lower refracture rate than patients in the control period.  However, there were more 
deaths in the cohort period despite the fact that there was no difference in age between groups 
nor a difference in the proportion of femur fractures, known to have increased mortality.  Due to 
this increased death rate in the cohort period, competing risks regression was used to 
determine if there was a difference in refracture rates after deaths were taken into account.  
Controlling for death, the cohort period had a significantly lower refracture rate than the control 
period.  
 
This study showed that a part-time nurse-led model of care for osteoporosis without a specialist 
clinic was associated with only a modest impact on outcomes after MTF.  The reality is that 
many regional and rural areas do not have specialist clinics, so other means to strengthen the 
FLS are needed.  One area for future research involves better co-ordination of discharge care 
follow-up between hospitals, orthopaedic surgeons and general practitioners.  
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Table 1: Characteristics of eligible and recruited participants 
    Eligible    Recruited   
    
Control 
(n=131) 
Cohort 
(n=328) 
All† 
(n=461) 
 
Control 
(n=47) 
Cohort 
(n=93) 
All 
(n=140) 
Female (%) 75.6 74.2 74.6  80.9 75.3 77.1 
Age [mean (SD)] 
77.1 
(13.1) 
76.1 
(12.5) 
76.4 
(12.7) 
 
75.8 
(11.8) 
71.3 
(11.5) 
72.8 
(11.8) 
Fracture Type (%)‡        
 femur 52.7 47.6 49.0  39.8 41.4 41.3 
 wrist 18.3 20.3 19.7  22.6 22.1 21.7 
 pelvis 4.6 6.4 5.9  5.4 5.7 5.8 
 tibia/fibula 9.9 3.9 5.6  3.2 5.7 5.8 
 ankle 5.3 10.3 8.9  17.2 14.3 14.5 
 humerus 9.2 10.0 9.8  11.8 10.7 10.9 
  >1 fracture 0 1.5 1.1   0 0 0 
* significant difference between control and cohort groups at p<0.05 
† includes 42 patients who died prior to recruitment 
‡ Values may not equal 100% due to rounding 
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Table 2: Percentages†of patients who received BMD scans, medication type and treatment after 
minimal trauma fracture in recruited control and cohort groups according to self-report 
    
Control 
(n=47) 
Cohort 
(n=93) 
All patients 
(n=140) 
BMD scan (%)    
 after fracture 40.9 40.5 40.6 
 ever had one 79.4 76.6 77.5 
Medications (%)    
 none 27.7 31.9 30.5 
 supplements 27.7 35.1 32.6 
 bisphosphonates or equivalent
‡ 44.7 33.0 36.9 
Treatment initiated or reviewed after 
fracture (%) 
   
 No/unchanged after fracture 74.5 57.4 63.1 
  Yes 25.5 42.6 36.9 
† Values may not equal 100% due to rounding 
‡ equivalent medications such as denosumab or strontium 
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Table 3: Refracture (same or different bone) within three years in the control and cohort groups 
for eligible patients  
Initial fracture type 
Refracture [n(%)] 
Control Cohort All patients 
Femur** 16 (23.2) 13 (8.3) 29 (12.8) 
wrist 5 (20.8) 9 (13.4) 14 (15.4) 
pelvis 0 3 (14.3) 3 (11.1) 
tibia/fibula 0 2 (15.4) 2 (7.7) 
ankle 2 (28.6) 4 (11.8) 6 (14.6) 
humerus 2 (16.7) 3 (9.1) 5 (11.1) 
Total* 25 (19.1) 34 (10.5) 59 (12.9) 
* significant difference between control and cohort groups at p<0.05 
** significant difference between control and cohort groups at p<0.01 
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Table 4: Death within three years in the control and cohort groups for eligible patients 
Initial fracture type  
Death [n(%)] 
Control Cohort All patients 
Femur 13 (18.8) 47 (29.9) 60 (26.5) 
wrist 1(4.2) 0 (13.4) 10 (11.0) 
pelvis 0 6 (28.6) 6 (22.2) 
tibia/fibula 0 4 (30.8) 4 (25.4) 
ankle 0 0 0 
humerus 2 (16.7) 1 (3.0) 3 (6.7) 
Total* 16 (12.2) 67 (20.6) 83 (18.2) 
* significant difference between control and cohort groups at p<0.05 
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Figure 1 
 
 
 
